Genocea Biosciences (GNCA) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock GNCA vs. NAVB, SCPS, EVLO, CMRA, GNCAQ, AMPE, ARDS, STAB, EFTR, and HSTOShould you be buying Genocea Biosciences stock or one of its competitors? The main competitors of Genocea Biosciences include Navidea Biopharmaceuticals (NAVB), Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Ampio Pharmaceuticals (AMPE), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), eFFECTOR Therapeutics (EFTR), and Histogen (HSTO). These companies are all part of the "pharmaceutical products" industry. Genocea Biosciences vs. Its Competitors Navidea Biopharmaceuticals Scopus BioPharma Evelo Biosciences Comera Life Sciences Genocea Biosciences Ampio Pharmaceuticals Aridis Pharmaceuticals Statera Biopharma eFFECTOR Therapeutics Histogen Genocea Biosciences (NASDAQ:GNCA) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership. Does the media prefer GNCA or NAVB? In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score. Company Overall Sentiment Genocea Biosciences Neutral Navidea Biopharmaceuticals Neutral Do insiders & institutionals hold more shares of GNCA or NAVB? 0.6% of Genocea Biosciences shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility and risk, GNCA or NAVB? Genocea Biosciences has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500. Is GNCA or NAVB more profitable? Navidea Biopharmaceuticals' return on equity of 0.00% beat Genocea Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Genocea BiosciencesN/A -182.88% -62.76% Navidea Biopharmaceuticals N/A N/A N/A Which has higher earnings and valuation, GNCA or NAVB? Navidea Biopharmaceuticals has lower revenue, but higher earnings than Genocea Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenocea Biosciences$1.91M0.00-$33.20M-$0.61N/ANavidea Biopharmaceuticals$8.13K2.46-$15.18MN/AN/A SummaryNavidea Biopharmaceuticals beats Genocea Biosciences on 5 of the 7 factors compared between the two stocks. Get Genocea Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GNCA and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNCA vs. The Competition Export to ExcelMetricGenocea BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$6K$276.97M$5.61B$9.30BDividend YieldN/AN/A4.23%4.03%P/E Ratio0.00N/A28.5219.58Price / SalesN/A432.09426.1793.37Price / CashN/A22.4436.0257.93Price / BookN/A9.478.135.54Net Income-$33.20M-$110.10M$3.24B$257.73M Genocea Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070NAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-80.0%$20K$8.13K0.0010SCPSScopus BioPharmaN/A$0.00flatN/AN/A$13KN/A0.009EVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120CMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070AMPEAmpio PharmaceuticalsN/A$0.00+3,900.0%N/A-88.9%$5KN/A0.0020Gap UpARDSAridis PharmaceuticalsN/A$0.00flatN/A-99.8%$5KN/A0.0030STABStatera BiopharmaN/A$0.00flatN/A-83.3%$5KN/A0.0020News CoverageEFTReFFECTOR Therapeutics0.0766 of 5 stars$0.00-33.3%N/A-99.7%$1KN/A0.0010Gap DownHSTOHistogenN/A$0.00flatN/A-83.3%$1K$19K0.0020 Related Companies and Tools Related Companies NAVB Competitors SCPS Competitors EVLO Competitors CMRA Competitors GNCAQ Competitors AMPE Competitors ARDS Competitors STAB Competitors EFTR Competitors HSTO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNCA) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genocea Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genocea Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GNCA Stock Alerts